2RH Stock Chart & Stats
€8.00
€0.00(0.00%)
At close: 4:00 PM EDT
€8.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€7.33 - €8.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.60M
Enterprise Value€1.05M
Total Cash (Recent Filing)€2.87M
Total Debt (Recent Filing)€214.00K
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Mar 18, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding8,887,684
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.76
Price to Sales (P/S)11.38
P/FCF Ratio-0.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€45.05M
Bulls Say, Bears Say
Bulls Say
GI Portfolio ExpansionThe long-term rights to Rebyota and Clenpiq create a more substantial commercial platform around established, FDA-approved GI products. Their reported $37.5 million of 2025 sales under Ferring provides a meaningful base for RedHill’s future commercialization strategy and supports broader market positioning.
Liquidity ImprovementThe Talicia divestiture supplied substantial upfront cash while preserving potential milestone participation. Redeploying proceeds into GI commercialization improves near-term financial flexibility and gives management resources to build a larger product platform without relying solely on operating revenue.
Pipeline Development SupportExternal NCI funding supports a structured clinical program that expands opaganib into ultra-high-risk multiple myeloma. The planned Phase 1b and Phase 2 studies provide a pathway to generate additional clinical evidence and broaden the pipeline’s potential oncology applications.
Bears Say
Revenue CollapseThe steep revenue contraction indicates that RedHill’s historical commercial base has not produced durable top-line performance. Until the newer GI rights generate reported sales at scale, the company remains exposed to a prolonged transition period with limited operating revenue.
Persistent Cash BurnSustained negative operating and free cash flow means the business is not currently self-funding its operations. Continued cash consumption can restrict investment in commercialization and development, while increasing reliance on financing or asset transactions to maintain business activities.
Financing And Listing PressureExpanding the ATM facility shows that equity financing remains an important source of capital, while the bid-price extension highlights continuing exchange-compliance pressure. These conditions can complicate capital planning and weaken flexibility during the commercial transition.
RedHill Biopharma News
2RH FAQ
What was RedHill Biopharma’s price range in the past 12 months?
RedHill Biopharma lowest stock price was €7.33 and its highest was €8.00 in the past 12 months.
What is RedHill Biopharma’s market cap?
RedHill Biopharma’s market cap is €3.60M.
When is RedHill Biopharma’s upcoming earnings report date?
RedHill Biopharma’s upcoming earnings report date is Mar 18, 2027 which is in 145 days.
How were RedHill Biopharma’s earnings last quarter?
RedHill Biopharma released its earnings results on Sep 30, 2026. The company reported -€0.899 earnings per share for the quarter.
Is RedHill Biopharma overvalued?
According to Wall Street analysts RedHill Biopharma’s price is currently Overvalued.
Does RedHill Biopharma pay dividends?
RedHill Biopharma does not currently pay dividends.
What is RedHill Biopharma’s EPS estimate?
RedHill Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RedHill Biopharma have?
RedHill Biopharma has 8,887,684 shares outstanding.
What happened to RedHill Biopharma’s price movement after its last earnings report?
RedHill Biopharma reported an EPS of -€0.899 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of RedHill Biopharma?
Currently, no hedge funds are holding shares in DE:2RH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RedHill Biopharma
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Technical Analysis
Ironwood Pharma
―
Perrigo Company
―
SIGA Technologies
―
Teva
―
Takeda Pharmaceutical Company
―